Document Detail


Intrapericardial ranolazine prolongs atrial refractory period and markedly reduces atrial fibrillation inducibility in the intact porcine heart.
MedLine Citation:
PMID:  20075744     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Extensive experimental studies and clinical evidence (Metabolic Efficiency with Ranzolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction-36 [MERLIN TIMI-36] trial) indicate potential antiarrhythmic efficacy of the antianginal agent ranolazine. Delivery of agents into the pericardial space allows high local concentrations to be maintained in close proximity to myocardial tissue while systemic effects are minimized. METHODS AND RESULTS: The effects of intrapericardial (IPC) administration of ranolazine (50-mg bolus) on right atrial and right ventricular effective refractory periods (ERP), atrial fibrillation threshold, and ventricular fibrillation threshold were determined in 17 closed-chest anesthetized pigs. IPC ranolazine increased atrial ERP in a time-dependent manner from 129 +/- 5.14 to 186 +/- 9.78 ms (P < 0.01, N = 7) but did not significantly affect ventricular ERP (from 188.3 +/- 4.6 to 201 +/- 4.3 ms (NS, N = 6). IPC ranolazine increased atrial fibrillation threshold from 4.8 +/- 0.8 to 28 +/- 2.3 mA (P < 0.03, N = 6) and ventricular fibrillation threshold (from 24 +/- 3.56 baseline to 29.33 +/- 2.04 mA at 10-20 minutes, P < 0.03, N = 6). No significant change in mean arterial pressure was observed (from 92.8 +/- 7.1 to 74.8 +/- 7.5 mm Hg, P < 0.125, N = 5, at 7 minutes). CONCLUSIONS: IPC ranolazine exhibits striking atrial antiarrhythmic actions as evidenced by increases in refractoriness and in fibrillation inducibility without significantly altering mean arterial blood pressure. Ranolazine's effects on the atria appear to be more potent than those on the ventricles.
Authors:
Marcelo Carvas; Bruno C G Nascimento; Mariana Acar; Bruce D Nearing; Luiz Belardinelli; Richard L Verrier
Related Documents :
11992024 - Dual site right atrial pacing in the prevention of symptomatic atrial fibrillation refr...
15680854 - Effects of methylprednisolone and a biocompatible copolymer circuit on blood activation...
15919294 - Determination of histopathologic risk factors for postoperative atrial fibrillation in ...
53494 - Pericarditis in acute myocardial infarction.
14654574 - Drug therapy in chronic heart failure.
8489834 - Acute electrolyte disturbances in coronary sinus during left coronary arteriography in ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  55     ISSN:  1533-4023     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-04-14     Completed Date:  2010-07-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  286-91     Citation Subset:  IM    
Affiliation:
University of São Paulo School of Medicine, São Paulo, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acetanilides / administration & dosage,  pharmacology*
Animals
Anti-Arrhythmia Agents / administration & dosage,  pharmacology*
Atrial Fibrillation / drug therapy*,  physiopathology
Blood Pressure / drug effects
Disease Models, Animal
Female
Injections
Male
Piperazines / administration & dosage,  pharmacology*
Refractory Period, Electrophysiological / drug effects
Swine
Time Factors
Ventricular Fibrillation / drug therapy*,  physiopathology
Chemical
Reg. No./Substance:
0/Acetanilides; 0/Anti-Arrhythmia Agents; 0/Piperazines; 110445-25-5/ranolazine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Activation of Cannabinoid CB2 Receptor Ameliorates Atherosclerosis Associated with Suppression of Ad...
Next Document:  Paclitaxel potentiates inflammatory cytokine-induced prothrombotic molecules in endothelial cells.